People in the News
As it prepares to expand and advance its MyProstateScore risk test, LynxDx has hired Jeremiah Johnson as is VP of sales and Shawn Wheeler as its senior director of market access.
Johnson has more than 20 years of experience in the diagnostic, medical, biotechnology, and pharmaceutical industries, most recently serving as senior west region sales manager at Exact Sciences. Prior to that, he served as senior urology sales representative at Endo Health Solutions.
Wheeler boasts more than 15 years in pharmaceutical and diagnostic sales. He joins LynxDx from a decade-long career at Exact Sciences, most recently as national accounts manager for commercial markets.
Sasha King announced her intent to resign as chief marketing officer of CareDx, effective as of the end of the day on Sept. 16, in order to pursue another career opportunity. A filing with the US Securities and Exchange Commission stated that King's resignation is not a result of any disagreement with CareDx and that she will continue to provide consulting services for the company for "a period of time following her resignation."
Medix Biochemica, a supplier of raw materials to the in vitro diagnostics industry, has appointed Michele Pedrocchi to its board of directors. Pedrocchi is a former global head of strategy and business development for diagnostics at Roche. He has been working as an independent strategic advisor and non-executive director to private and public healthcare companies.
Nanomix has appointed Tadd Lazarus to its board of directors as an independent director. Lazarus has served as chief medical officer at multiple biotechnology companies, including Achieve Health Management, Inivata, and Clinical Genomics. From 2013 to 2016, he was CMO and head of medical and scientific affairs, reimbursement, and public policy at Qiagen and before that served as CMO and VP of clinical affairs at Gen-Probe (now Hologic). Lazarus also held multiple positions at Roche Diagnostics, including director of medical and scientific affairs and North American medical director for the molecular diagnostics, point-of-care, diabetes, clinical chemistry, and immunology businesses.
Sema4 has promoted Kevin Feeley to CFO. Feeley will also keep his titles of VP of operations and head of GeneDx, the molecular diagnostics brand that Sema4 acquired from Opko Health in May for $623 million. Feeley previously served as CFO of GeneDx and BioReference Laboratories. Sema4's former CFO, Isaac Ro, left the company earlier this month.
HTG Molecular Diagnostics has appointed Thomas Dubensky to its board of directors. Dubensky was the founding CEO of Tempest Therapeutics and currently serves as president of that company. He has also previously served as CSO of Aduro Biotech, Immune Design, and Anza Therapeutics, which he also cofounded.
Precipio has appointed Sharon Robins as senior director of laboratory and hospital sales within the company's products division. She has been the director of molecular diagnostics at Qiagen, and she previously worked in senior sales positions for Quest Diagnostics, Thermo Fisher Scientific, and Life Technologies, now part of Thermo Fisher.
Precipio is launching its HemeScreen cancer diagnostic assay line, and Robins will manage the company's relationship with Thermo Fisher, which has a first-year target of $10 million in revenue from distributing the assays in a partnership announced in July.
The Binding Site has appointed Mark Stevenson as its non-executive chairperson. He is currently on the board of Ingersoll Rand and the Personalized Medicine Coalition. Stevenson was the EVP and COO of Thermo Fisher Scientific. Before joining Thermo Fisher, he was president and COO of Life Technologies, which was acquired by Thermo Fisher. Prior to that, he was president and COO of Applied Biosystems before it merged with Invitrogen. The Binding Site was founded by researchers at the University of Birmingham in 1983. It operates in the immunodiagnostic spac and has more than 1,400 instruments installed globally.
Mainz Biomed has appointed Kim Turgeon to its medical advisory board. Turgeon is a clinical professor at University of Michigan Health and a clinical translational researcher who specializes in colon cancer and chemoprevention. He also has been a co-lead of the Barrett's Esophagus Translational Research Network sponsored by the National Cancer Institute.
Germany-based Mainz's medical advisory board is supporting an upcoming US trial for its ColoAlert DNA assay for markers of colorectal cancer as well as helping evaluate ColoAlert's potential uses in other oncology indications and potential to enhance Mainz's product pipeline.
Capsulomics has appointed Stacey Gilbert as vice president of market access and reimbursement and Lisa Kann as vice president of product development and strategy.
Gilbert will lead efforts to optimize government and private companies' coverage, coding, and reimbursement for Capsulomics' testing portfolio. Before joining Capsulomics, she was the senior director of population health and director of market access strategy for Exact Sciences. She also has prior experience in sales and market access at Sankyo Pharma, CV Therapeutics, Gilead Sciences, Zoll LifeVest, SomnoMed, and Medac Pharma.
Kann was previously the director of lab planning and project management at Thrive Earlier Detection, which was acquired by Exact Sciences in 2021. She also was head of laboratory operations at Papgene, VP of laboratory operations at Personal Genome Diagnostics, scientist and manager at Genzyme Genetics, and principal scientist at Exact Sciences.